Benitec Biopharma’s $18 Million Stock Offering

Proskauer advised Benitec Biopharma on the transaction.Benitec Biopharma (Nasdaq: BNTC), a development-stage, gene therapy-focused, biotechnology company, closed its recent capital raise. The aggregate gross proceeds to Benitec from the…